FORM 4

Check this box if no

16. Form 4 or Form 5

obligations may

1(b).

longer subject to Section

continue. See Instruction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB 3235-0287 Number: December 31, Expires:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

Estimated average burden hours per response 0.5

1. Name and Address of Reporting Person* Akirov Alfred			2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	(First) LIX BIOTHEF	(Middle) RAPEUTICS, , SCIENCE PARK,	3. Date of Earliest Transaction (Month/Day/Year) 08/14/2013	X Director Officer (give title below)	10% Owner Other (specify below)			
(Street) CARMIEL (City)	et)		4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code		4. Secur Acquired Disposed (Instr. 3,	(A)	or (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D)	Beneficial Ownership	
			Code	V	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock	08/14/2013		S		100,000	D	\$ 5.05	4,927,713	ı	By Corporation	
Common Stock	08/14/2013		S		5,000	D	\$ 5.07	4,922,713	ı	By Corporation	
Common Stock	08/14/2013		S		5,000	D	\$ 5.08	4,917,713	ı	By Corporation	
Common Stock	08/15/2013		S		2,330	D	\$ 5.07	4,915,383	ı	By Corporation	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Secur Acqui (A) or Dispos of (D) (Instr. 8)		5. 6. Date Number of Exercisable Derivative Securities Acquired (A) or Disposed		Date	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. All sales reported on this Form 4 were made by Alrov (Israel) Ltd.("Alrov Israel") and the column in Table 1 disclosing the amount of securities beneficially owned following the reported transactions includes 686,046 shares of the Issuer's common stock held by Technorov Holdings (1993) Ltd. ("Technorov"). Alrov Israel owns 100% of Al-Rov Technologies Holdings LTD, the holder of 80% of Technorov. The reporting person is the Chairman of Alrov Israel and the Chief Executive Officer of Technorov, and has the power to control their respective investment decisions. Alrov Israel is an Israeli publicly-traded company that is listed on the Tel Aviv Stock Exchange. The reporting person disclaims beneficial ownership of the securities of the Issuer held by Alrov Israel and Technorov, except to the extent of his proportional pecuniary interest therein.

/s/ Yossi Maimon, POA 08/16/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.